- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Genetic Recombination.
Displaying page 1 of 1.
EudraCT Number: 2018-002966-37 | Sponsor Protocol Number: 1-2018BSMO | Start Date*: 2019-01-23 |
Sponsor Name:Belgian Society of Medical Oncology | ||
Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. | ||
Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000838-19 | Sponsor Protocol Number: N12OLG | Start Date*: 2012-06-26 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency | |||||||||||||
Medical condition: Oligo metastatic breast cancer harboring homologous recombination deficiency and/or the patient has a deleterious germline BRCA1 or BRCA2 mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000750-22 | Sponsor Protocol Number: GHLIQUID-4020 | Start Date*: 2018-04-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial investigating the long-term efficacy and safety of two doses of NN-220 (somatropin [genetical recombination]) in short stature due to Noonan syndrome | |||||||||||||
Medical condition: Noonan Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000298-11 | Sponsor Protocol Number: ISS22810078 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "ISTITUTI OSPITALIERI" DI CREMONA | |||||||||||||
Full Title: A phase II, open label, controlled study of olaparib in locally advanced ER, PgR and HER2 negative (Triple Negative) and in locally advanced germline BRCA mutation-positive breast cancer patients: ... | |||||||||||||
Medical condition: Locally advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002949-42 | Sponsor Protocol Number: PACT-29 | Start Date*: 2020-11-27 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing a germ line BRCA or other DNA Defects Repair (DDR) mutations. | |||||||||||||
Medical condition: Patients affected by metastatic pancreatic adenocarcinoma (PDAC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007725-46 | Sponsor Protocol Number: ASBI 307 | Start Date*: 2009-02-06 |
Sponsor Name:Asubio Pharmaceuticals, Inc. | ||
Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 We... | ||
Medical condition: Cachexia associated with chronic obstructive pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004269-26 | Sponsor Protocol Number: ENGOT-ov24-NSGO | Start Date*: 2015-05-22 | |||||||||||||||||||||
Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit | |||||||||||||||||||||||
Full Title: Niraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Part 1: AVANOVA1 - A phase I study to evaluate the saf... | |||||||||||||||||||||||
Medical condition: Women with relapsed platinum-sensitive epithelial ovarian cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) SE (Completed) NO (Ongoing) FI (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003439-18 | Sponsor Protocol Number: D0810C00019 | Start Date*: 2009-02-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor... | |||||||||||||
Medical condition: platinum sensitive serous ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001469-26 | Sponsor Protocol Number: SOGUG-2016-A-IEC(PRO)-12 | Start Date*: 2017-12-27 | |||||||||||
Sponsor Name:Spanish Oncology Genitourinary Group – SOGUG | |||||||||||||
Full Title: Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response. | |||||||||||||
Medical condition: Metastasic Prostate Cancer Resistant to Castration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004738-39 | Sponsor Protocol Number: ENGOT-OV56/NSGO-CTU-DOVACC | Start Date*: 2021-08-20 | |||||||||||
Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit | |||||||||||||
Full Title: ENGOT-OV56-NSGO-CTU-DOVACC. A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer. | |||||||||||||
Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Ongoing) NO (Ongoing) LT (Ongoing) SE (Ongoing) DE (Ongoing) FI (Ongoing) GR (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003509-41 | Sponsor Protocol Number: GBG90 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien... | |||||||||||||
Medical condition: Patients with triple negative or HRpositive, early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000423-12 | Sponsor Protocol Number: CP506-001 | Start Date*: 2022-12-13 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Maastricht University | ||||||||||||||||||||||||||||||||||||||
Full Title: A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic ... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Tumour Agnostic treatment. ● Module differentiation: – Module 1 - monotherapy – solid tumour patients with cancer types that are enriched for HRD/FAD defects – Module 2 – combination with Carboplat... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004118-16 | Sponsor Protocol Number: MK-7339-010 | Start Date*: 2019-04-15 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC... | |||||||||||||
Medical condition: Metastatic Castration resistant Prostate Cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.